
Naoki Okada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1635775/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of immune response induction mechanisms implicating the dose-sparing effect of transcutaneous immunization using a self-dissolving microneedle patch. Vaccine, 2022, 40, 862-872.	3.8	1
2	Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells. Pharmaceutics, 2022, 14, 385.	4.5	1
3	The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity. International Journal of Molecular Sciences, 2022, 23, 4056.	4.1	7
4	Targeting GGT1 Eliminates the Tumor-Promoting Effect and Enhanced Immunosuppressive Function of Myeloid-Derived Suppressor Cells Caused by G-CSF. Frontiers in Pharmacology, 2022, 13, 873792.	3.5	4
5	Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors. Biomedicines, 2022, 10, 1273.	3.2	1
6	Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals. International Journal of Molecular Sciences, 2021, 22, 2476.	4.1	10
7	Characteristics of immune induction by transcutaneous vaccination using dissolving microneedle patches in mice. International Journal of Pharmaceutics, 2021, 601, 120563.	5.2	9
8	Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice. Vaccines, 2021, 9, 1480.	4.4	0
9	Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting) Tj ETQq1 1	0.784314	rgBT /Overlo
10	Transcutaneous immunization with a highly active form of XCL1 as a vaccine adjuvant using a hydrophilic gel patch elicits long-term CD8+ T cell responses. Journal of Pharmacological Sciences, 2020, 143, 182-187.	2.5	6
11	Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells, 2020, 9, 1182.	4.1	81
12	Characteristic of K3 (CpC-ODN) as a Transcutaneous Vaccine Formulation Adjuvant. Pharmaceutics, 2020, 12, 267.	4.5	11
13	Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. Oncolmmunology, 2020, 9, 1734268.	4.6	24
14	Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochemical and Biophysical Research Communications, 2020, 527, 350-357.	2.1	45
15	Immunogenicity of Milk Protein-Containing Hydrophilic Gel Patch for Epicutaneous Immunotherapy for Milk Allergy. Pharmaceutical Research, 2020, 37, 35.	3.5	12
16	Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. IUBMB Life, 2020, 72, 1649-1658.	3.4	2
17	Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells. Journal of Pharmacological Sciences, 2018, 137, 359-365.	2.5	31
18	Clinical study of a retinoic acid-loaded microneedle patch for seborrheic keratosis or senile lentigo. Life Sciences, 2017, 168, 24-27.	4.3	29

#	Article	IF	CITATIONS
19	Development of novel double-decker microneedle patches for transcutaneous vaccine delivery. International Journal of Pharmaceutics, 2017, 532, 374-383.	5.2	35
20	Related Topic: Vaccines. , 2017, , 281-288.		0
21	Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9, 27.	4.5	27
22	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Molecular Therapy - Oncolytics, 2016, 3, 16024.	4.4	17
23	Analysis of Skin Permeability and Toxicological Properties of Amorphous Silica Particles. Biological and Pharmaceutical Bulletin, 2016, 39, 1201-1205.	1.4	16
24	Development of a Patch Vaccine Formulation Utilizing the Microneedle Technology. Journal of the Japan Society for Precision Engineering, 2016, 82, 1023-1026.	0.1	0
25	Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy. Biochemical and Biophysical Research Communications, 2016, 473, 73-79.	2.1	15
26	Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials, 2015, 57, 50-58.	11.4	439
27	Potential of epicutaneous immunotherapy using a novel device. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2015, 29, 49-53.	0.2	0
28	Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease. Journal of Neuroimmunology, 2014, 266, 1-11.	2.3	47
29	Development and Clinical Study of a Self-Dissolving Microneedle Patch for Transcutaneous Immunization Device. Pharmaceutical Research, 2013, 30, 2664-2674.	3.5	343
30	Development of a novel therapeutic approach using a retinoic acid-loaded microneedle patch for seborrheic keratosis treatment and safety study in humans. Journal of Controlled Release, 2013, 171, 93-103.	9.9	39
31	Analysis of Transcutaneous Antigenic Protein Delivery by a Hydrogel Patch Formulation. Journal of Pharmaceutical Sciences, 2013, 102, 1936-1947.	3.3	17
32	Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy. Cytokine, 2013, 61, 578-584.	3.2	4
33	Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system. International Journal of Pharmaceutics, 2013, 441, 570-579.	5.2	81
34	Transcutaneous vaccines – current and emerging strategies. Expert Opinion on Drug Delivery, 2013, 10, 485-498.	5.0	24
35	Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery. Vaccine, 2013, 31, 2403-2415.	3.8	46
36	Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. Blood, 2013, 121, 2804-2813.	1.4	30

#	Article	IF	CITATIONS
37	Suppression of nanosilica particle-induced inflammation by surface modification of the particles. Archives of Toxicology, 2012, 86, 1297-1307.	4.2	49
38	Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine, 2012, 30, 1847-1854.	3.8	32
39	Optimization and Internalization Mechanisms of PEGylated Adenovirus Vector with Targeting Peptide for Cancer Gene Therapy. Biomacromolecules, 2012, 13, 2402-2409.	5.4	26
40	A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. Journal of Controlled Release, 2012, 161, 10-17.	9.9	108
41	Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. Journal of Controlled Release, 2012, 160, 495-501.	9.9	124
42	Lysine-deficient lymphotoxin-Î \pm mutant for site-specific PEGylation. Cytokine, 2011, 56, 489-493.	3.2	3
43	Structure–activity relationship of T-cell receptors based on alanine scanning. Biochemical and Biophysical Research Communications, 2011, 415, 558-562.	2.1	2
44	Compositional Optimization and Safety Assessment of a Hydrogel Patch as a Transcutaneous Immunization Device. Biological and Pharmaceutical Bulletin, 2011, 34, 1835-1840.	1.4	11
45	Characterization of Transcutaneous Protein Delivery by a Hydrogel Patch in Animal, Human, and Tissue-Engineered Skin Models. Biological and Pharmaceutical Bulletin, 2011, 34, 586-589.	1.4	18
46	Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. Journal of Controlled Release, 2011, 149, 15-20.	9.9	54
47	Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. Journal of Controlled Release, 2011, 152, 310-316.	9.9	53
48	Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif. Journal of Bioscience and Bioengineering, 2011, 111, 597-599.	2.2	4
49	Induction of Endoplasmic Reticulum–Endosome Fusion for Antigen Cross-Presentation Induced by Poly (γ-Glutamic Acid) Nanoparticles. Journal of Immunology, 2011, 187, 6249-6255.	0.8	36
50	Tumor Vascular Targeted Delivery of Polymer-conjugated Adenovirus Vector for Cancer Gene Therapy. Molecular Therapy, 2011, 19, 1619-1625.	8.2	31
51	Adenovirus Vector Covalently Conjugated to Polyethylene Glycol with a Cancer-Specific Promoter Suppresses the Tumor Growth through Systemic Administration. Biological and Pharmaceutical Bulletin, 2010, 33, 1073-1076.	1.4	11
52	Optimized PEGylated Adenovirus Vector Reduces the Anti-vector Humoral Immune Response against Adenovirus and Induces a Therapeutic Effect against Metastatic Lung Cancer. Biological and Pharmaceutical Bulletin, 2010, 33, 1540-1544.	1.4	34
53	The Utility of Poly(.GAMMAglutamic acid) Nanoparticles as Antigen Delivery Carriers in Dendritic Cell-Based Cancer Immunotherapy. Biological and Pharmaceutical Bulletin, 2010, 33, 2003-2007.	1.4	17
54	Enhanced Permeability of Insulin across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption-enhancing Mechanism of n-Lauryl-β-D-maltopyranoside. Journal of Pharmacy and Pharmacology, 2010, 51, 1241-1250.	2.4	134

#	Article	IF	CITATIONS
55	Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. Journal of Pharmacy and Pharmacology, 2010, 60, 1633-1641.	2.4	24
56	Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials, 2010, 31, 3357-3363.	11.4	13
57	Creation of lysine-deficient mutant lymphotoxin- $\hat{l}\pm$ with receptor selectivity by using a phage display system. Biomaterials, 2010, 31, 1935-1943.	11.4	12
58	The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1Î ² production, ROS production and endosomal rupture. Biomaterials, 2010, 31, 6833-6842.	11.4	136
59	Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models. International Immunopharmacology, 2010, 10, 26-33.	3.8	2
60	Titanium dioxide induces different levels of IL-1β production dependent on its particle characteristics through caspase-1 activation mediated by reactive oxygen species and cathepsin B. Biochemical and Biophysical Research Communications, 2010, 392, 160-165.	2.1	83
61	Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2. Biochemical and Biophysical Research Communications, 2010, 394, 54-58.	2.1	6
62	Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor. Biochemical and Biophysical Research Communications, 2010, 393, 888-893.	2.1	10
63	Simple PEG Conjugation of SPIO via an Auâ^'S Bond Improves Its Tumor Targeting Potency as a Novel MR Tumor Imaging Agent. Bioconjugate Chemistry, 2010, 21, 1026-1031.	3.6	28
64	Development of transcutaneous vaccine formulations based on DDS technology. Drug Delivery System, 2010, 25, 8-14.	0.0	0
65	A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. Journal of Controlled Release, 2009, 133, 198-205.	9.9	85
66	Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. Biomaterials, 2009, 30, 1809-1814.	11.4	62
67	NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy. Cancer Immunology, Immunotherapy, 2009, 58, 291-299.	4.2	19
68	LIGHT protein suppresses tumor growth by augmentation of immune response. Immunology Letters, 2009, 127, 33-38.	2.5	9
69	Transduction of adenovirus vectors modified with cell-penetrating peptides. Peptides, 2009, 30, 1548-1552.	2.4	22
70	Immune Cell Recruitment and Cell-Based System for Cancer Therapy. Pharmaceutical Research, 2008, 25, 752-768.	3.5	35
71	Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin 12, elicits notably enhanced anti-tumor responses. Cancer Immunology, Immunotherapy, 2008, 57, 1657-1664.	4.2	10
72	Development of PEGylated adenovirus vector with targeting ligand. International Journal of Pharmaceutics, 2008, 354, 3-8.	5.2	78

#	Article	IF	CITATIONS
73	Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector variants. Virology, 2008, 374, 411-420.	2.4	8
74	A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. Journal of Controlled Release, 2008, 131, 113-120.	9.9	78
75	Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sciences, 2008, 83, 747-755.	4.3	15
76	Ligand-independent assembly of purified soluble magic roundabout (Robo4), a tumor-specific endothelial marker. Protein Expression and Purification, 2008, 61, 78-82.	1.3	4
77	Nanoparticles built by self-assembly of amphiphilic Î ³ -PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells. Vaccine, 2008, 26, 1303-1313.	3.8	79
78	Development of amphiphilic Î ³ -PGA-nanoparticle based tumor vaccine: Potential of the nanoparticulate cytosolic protein delivery carrier. Biochemical and Biophysical Research Communications, 2008, 366, 408-413.	2.1	80
79	Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor. Biochemical and Biophysical Research Communications, 2008, 372, 821-825.	2.1	13
80	Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. Journal of Pharmacy and Pharmacology, 2008, 60, 1633-1641.	2.4	6
81	Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors. Human Gene Therapy, 2007, 18, 753-762.	2.7	83
82	Effects of Labrasol and Other Pharmaceutical Excipients on the Intestinal Transport and Absorption of Rhodamine123, a P-Glycoprotein Substrate, in Rats. Biological and Pharmaceutical Bulletin, 2007, 30, 1301-1307.	1.4	95
83	TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochemical and Biophysical Research Communications, 2007, 362, 419-424.	2.1	17
84	Efficient generation of antigen-specific cellular immunity by vaccination with poly(γ-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Biochemical and Biophysical Research Communications, 2007, 362, 1069-1072.	2.1	32
85	CCâ€chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumorâ€infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. International Journal of Cancer, 2007, 121, 2013-2022.	5.1	46
86	A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. Journal of Controlled Release, 2007, 117, 11-19.	9.9	22
87	Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. Journal of Controlled Release, 2007, 122, 102-110.	9.9	98
88	Colon-specific delivery and enhanced colonic absorption of [Asu1,7]-eel calcitonin using chitosan capsules containing various additives in rats. Journal of Drug Targeting, 2006, 14, 165-172.	4.4	28
89	Functional characterization of Na+-independent choline transport in primary cultures of neurons from mouse cerebral cortex. Neuroscience Letters, 2006, 393, 216-221.	2.1	30
90	Functional and molecular identification of sodium oupled dicarboxylate transporters in rat primary cultured cerebrocortical astrocytes and neurons. Journal of Neurochemistry, 2006, 97, 162-173.	3.9	72

#	Article	IF	CITATIONS
91	Fusogenic liposomes and their suitability for gene delivery. Future Lipidology, 2006, 1, 735-742.	0.5	4
92	Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma. Biological and Pharmaceutical Bulletin, 2006, 29, 100-104.	1.4	34
93	Dendritic Cells That Endocytosed Antigen-Containing IgG-Liposomes Elicit Effective Antitumor Immunity. Journal of Immunotherapy, 2006, 29, 165-174.	2.4	40
94	Non-Methylated CpG Motif Packaged into Fusogenic Liposomes Enhance Antigen-Specific Immunity in Mice. Biological and Pharmaceutical Bulletin, 2006, 29, 105-109.	1.4	18
95	Synthesis of 15,20-triamide analogue with polar substituent on the phenyl ring of arenastatin A, an extremely potent cytotoxic spongean depsipeptide. Bioorganic and Medicinal Chemistry, 2006, 14, 7446-7457.	3.0	21
96	Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. International Journal of Pharmaceutics, 2006, 313, 49-56.	5.2	114
97	The short consensus repeats 1 and 2, not the cytoplasmic domain, of human CD46 are crucial for infection of subgroup B adenovirus serotype 35. Journal of Controlled Release, 2006, 113, 271-278.	9.9	22
98	Excellent Absorption Enhancing Characteristics of NO Donors for Improving the Intestinal Absorption of Poorly Absorbable Compound Compared with Conventional Absorption Enhancers. Drug Metabolism and Pharmacokinetics, 2006, 21, 222-229.	2.2	14
99	Anti-tumor Responses Induced by Chemokine CCL19 Transfected into an Ovarian Carcinoma Model via Fiber-Mutant Adenovirus Vector. Biological and Pharmaceutical Bulletin, 2005, 28, 1066-1070.	1.4	26
100	Cell Delivery System: A Novel Strategy to Improve the Efficacy of Cancer Immunotherapy by Manipulation of Immune Cell Trafficking and Biodistribution. Biological and Pharmaceutical Bulletin, 2005, 28, 1543-1550.	1.4	7
101	Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. International Journal of Pharmaceutics, 2005, 293, 63-72.	5.2	19
102	Improvement of absorption enhancing effects of n-dodecyl-β-d-maltopyranoside by its colon-specific delivery using chitosan capsules. International Journal of Pharmaceutics, 2005, 293, 127-135.	5.2	38
103	Transport characteristics of N â€acetylâ€I â€aspartate in rat astrocytes: involvement of sodiumâ€coupled highâ€affinity carboxylate transporter NaC3/NaDC3â€mediated transport system. Journal of Neurochemistry, 2005, 93, 706-714.	3.9	40
104	Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Therapy, 2005, 12, 72-83.	4.6	47
105	Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Therapy, 2005, 12, 608-616.	4.6	22
106	Functional linkage of H+/peptide transporter PEPT2 and Na+/H+ exchanger in primary cultures of astrocytes from mouse cerebral cortex. Brain Research, 2005, 1044, 33-41.	2.2	31
107	Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu1,7]-eel calcitonin in rats. Journal of Controlled Release, 2005, 106, 287-297.	9.9	60
108	Chitosan Oligomers as Potential and Safe Absorption Enhancers for Improving the Pulmonary Absorption of Interferon-α in Rats. Journal of Pharmaceutical Sciences, 2005, 94, 2432-2440.	3.3	47

#	Article	IF	CITATIONS
109	Functional characterization of brain peptide transporter in rat cerebral cortex: identification of the high-affinity type H+/peptide transporter PEPT2. Brain Research, 2004, 997, 52-61.	2.2	42
110	Modulation of Intestinal P-Glycoprotein Function by Cremophor EL and Other Surfactants by an In Vitro Diffusion Chamber Method Using the Isolated Rat Intestinal Membranes. Journal of Pharmaceutical Sciences, 2004, 93, 877-885.	3.3	144
111	Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. International Journal of Pharmaceutics, 2004, 282, 141-149.	5.2	26
112	Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochimica Et Biophysica Acta - General Subjects, 2004, 1670, 172-180.	2.4	21
113	Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochemical and Biophysical Research Communications, 2004, 317, 68-76.	2.1	45
114	Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Therapy, 2003, 10, 421-431.	4.6	37
115	Enhanced transdermal delivery of phenylalanyl-glycine by chemical modification with various fatty acids. International Journal of Pharmaceutics, 2003, 250, 119-128.	5.2	20
116	Combination effects of complement regulatory proteins and anti-complement polymer. Biochimica Et Biophysica Acta - General Subjects, 2003, 1624, 54-59.	2.4	4
117	A novel cytomedical vehicle capable of protecting cells against complement. Biochemical and Biophysical Research Communications, 2003, 305, 353-358.	2.1	11
118	Enhanced Permeability of Phenylalanyl-glycine (Phe-Gly) Across the Intestinal Membranes by Chemical Modification with Various Fatty Acids. Drug Metabolism and Pharmacokinetics, 2003, 18, 23-32.	2.2	7
119	Development of a Novel Cytomedical Treatment that can Protect Entrapped Cells from Host Humoral Immunity. Cell Transplantation, 2002, 11, 787-797.	2.5	8
120	Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic β cell lines. Life Sciences, 2002, 71, 1717-1729.	4.3	18
121	Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. Cancer Letters, 2002, 177, 57-63.	7.2	21
122	Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. Journal of Controlled Release, 2002, 82, 51-61.	9.9	177
123	Tumor Necrosis Factor α-Gene Therapy for an Established Murine Melanoma Using RGB (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors. Japanese Journal of Cancer Research, 2002, 93, 436-444.	1.7	21
124	Efficient Gene Delivery into Dendritic Cells by Fiber-Mutant Adenovirus Vectors. Biochemical and Biophysical Research Communications, 2001, 282, 173-179.	2.1	83
125	Effects of lipofectin–antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochimica Et Biophysica Acta - General Subjects, 2001, 1527, 97-101.	2.4	23
126	Evaluation of Insulin Permeability and Effects of Absorption Enhancers on Its Permeability by an in Vitro Pulmonary Epithelial System Using Xenopus Pulmonary Membrane Biological and Pharmaceutical Bulletin, 2001, 24, 385-389.	1.4	19

#	Article	IF	CITATIONS
127	Enhanced Absorption of Insulin and (Asu1,7)Eelâ€Calcitonin using Novel Azopolymerâ€Coated Pellets for Colonâ€Specific Drug Delivery. Journal of Pharmaceutical Sciences, 2001, 90, 89-97.	3.3	52
128	Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. Journal of Controlled Release, 2001, 76, 363-374.	9.9	64
129	Enhanced absorption of insulin and (Asu1,7)eelâ€calcitonin using novel azopolymerâ€coated pellets for colonâ€specific drug delivery. Journal of Pharmaceutical Sciences, 2001, 90, 89-97.	3.3	4
130	Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats. Pharmaceutical Research, 2000, 17, 1461-1467.	3.5	39
131	Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: implication of high affinity type H+/peptide transporter PEPT2 mediated transport system. Neuroscience Letters, 1999, 271, 117-120.	2.1	30
132	Ï, Receptor Ligand-Induced Up-Regulation of the H+/Peptide Transporter PEPT1 in the Human Intestinal Cell Line Caco-2. Biochemical and Biophysical Research Communications, 1999, 261, 242-246.	2.1	50
133	Prolongation of the Effective Duration of Cytomedical Therapy by Re-injecting SK2 Hybridoma Cells Microencapsulated within Alginate-Poly(L)lysine-Alginate Membranes into Human Interleukin-6 Transgenic Mice Biological and Pharmaceutical Bulletin, 1999, 22, 295-297.	1.4	8
134	Antimetastatic effect of synthetic Glu-lle-Leu-Asp- Val peptide derivatives containing D-amino acids. Anti-Cancer Drugs, 1997, 8, 702-707.	1.4	17
135	Therapeutic Effect of Cytomedicine on Mesangio-Proliferative Glomerulonephritis in Human Interleukin-6 Transgenic Mice Biological and Pharmaceutical Bulletin, 1997, 20, 255-258.	1.4	12
136	Immunological Studies of SK2 Hybridoma Cells Microencapsulated with Alginate-Poly(L)lysine-Alginate (APA) Membrane Following Allogeneic Transplantation. Biochemical and Biophysical Research Communications, 1997, 230, 524-527.	2.1	35
137	Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(l) lysine-alginate membrane. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1360, 53-63.	3.8	27
138	Medical application of microencapsulating hybridoma cells in agarose microbeads `cytomedicine': therapeutic effect on IgG1 plasmacytosis and mesangio-proliferative glomerulonephritis in the interleukin 6 transgenic mouse. Journal of Controlled Release, 1997, 44, 195-200.	9.9	9
139	Selective Enhancement by Tumor Necrosis Factor-α of Vascular Permeability of New Blood Vessels Induced with Agarose Hydrogel-entrapped Meth-A Fibrosarcoma Cells. Japanese Journal of Cancer Research, 1996, 87, 831-836.	1.7	10
140	Evaluation of Angiogenic Inhibitors with anin vivoQuantitative Angiogenesis Method Using Agarose Microencapsulation and Mouse Hemoglobin Enzyme-linked Immunosorbent Assay. Japanese Journal of Cancer Research, 1996, 87, 952-957.	1.7	13
141	A Quantitativein vivoMethod of Analyzing Human Tumor-induced Angiogenesis in Mice Using Agarose Microencapsulation and Hemoglobin Enzyme-linked Immunosorbent Assay. Japanese Journal of Cancer Research, 1995, 86, 1182-1188.	1.7	15
142	Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. Journal of Controlled Release, 1995, 33, 447-451.	9.9	19
143	Antimetastatic effects of synthetic peptides containing the core sequence of the type III connecting segment domain (IIICS) of fibronectin. Anti-Cancer Drugs, 1994, 5, 424-428.	1.4	15